Edwards Lifesciences Unrecognized compensation cost related to non-vested awards decreased by 18.5% to $264.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.4%, from $239.30M to $264.30M. This is a positive signal — lower values indicate better performance for this metric.
An increasing balance suggests higher future non-cash compensation expenses, potentially impacting future earnings, while a decreasing balance indicates a reduction in future stock-based compensation drag.
This figure represents the total unrecognized compensation expense for equity-based awards granted to employees that hav...
Standard disclosure for all public companies using equity-based compensation; comparable across the asset management sector.
other_employee_service_share_based_compensation_nonveste_67563f| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $200.70M | $184.40M | $149.70M | $233.80M | $220.30M | $187.90M | $275.00M | $254.50M | $242.60M | $313.40M | $289.70M | $239.30M | $346.10M | $324.10M | $264.30M |
| QoQ Change | — | -8.1% | -18.8% | +56.2% | -5.8% | -14.7% | +46.4% | -7.5% | -4.7% | +29.2% | -7.6% | -17.4% | +44.6% | -6.4% | -18.5% |
| YoY Change | — | — | — | +16.5% | +19.5% | +25.5% | +17.6% | +15.5% | +29.1% | +14.0% | +13.8% | -1.4% | +10.4% | +11.9% | +10.4% |